China Reports One-Third Drop In Hep B Vaccinations Following Scandal
This article was originally published in PharmAsia News
China authorities report a 30% drop in vaccinations against hepatitis B in the wake of a scandal involving the three primary producers of the vaccine.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.